Literature DB >> 28505464

Treatment of the cardiac hypertrophic response and heart failure with ginseng, ginsenosides, and ginseng-related products.

Morris Karmazyn1, Xiaohong Tracey Gan1,1.   

Abstract

Heart failure is a major medical and economic burden throughout the world. Although various treatment options are available to treat heart failure, death rates in both men and women remain high. Potential adjunctive therapies may lie with use of herbal medications, many of which possess potent pharmacological properties. Among the most widely studied is ginseng, a member of the genus Panax that is grown in many parts of the world and that has been used as a medical treatment for a variety of conditions for thousands of years, particularly in Asian societies. There are a number of ginseng species, each possessing distinct pharmacological effects due primarily to differences in their bioactive components including saponin ginsenosides and polysaccharides. While experimental evidence for salutary effects of ginseng on heart failure is robust, clinical evidence is less so, primarily due to a paucity of large-scale well-controlled clinical trials. However, there is evidence from small trials that ginseng-containing Chinese medications such as Shenmai can offer benefit when administered as adjunctive therapy to heart failure patients. Substantial additional studies are required, particularly in the clinical arena, to provide evidence for a favourable effect of ginseng in heart failure patients.

Entities:  

Keywords:  cardiac hypertrophy; ginseng; ginsenosides; ginsénosides; heart failure; hypertrophie cardiaque; insuffisance cardiaque

Mesh:

Substances:

Year:  2017        PMID: 28505464     DOI: 10.1139/cjpp-2017-0092

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  4 in total

1.  Comparative transcriptome analysis of MeJA-responsive AP2/ERF transcription factors involved in notoginsenosides biosynthesis.

Authors:  Tingwen Lin; Jinfa Du; Xiaoyan Zheng; Ping Zhou; Ping Li; Xu Lu
Journal:  3 Biotech       Date:  2020-06-05       Impact factor: 2.406

2.  Investigation into the protective effects of hypaconitine and glycyrrhetinic acid against chronic heart failure of the rats.

Authors:  Liqin Wang; Haiming Deng; Tengyu Wang; Yun Qiao; Jianbing Zhu; Mingfeng Xiong
Journal:  BMC Complement Med Ther       Date:  2022-06-16

3.  Aminoacylase-1 plays a key role in myocardial fibrosis and the therapeutic effects of 20(S)-ginsenoside Rg3 in mouse heart failure.

Authors:  Qiong Lai; Fu-Ming Liu; Wang-Lin Rao; Guang-Ying Yuan; Zhao-Yang Fan; Lu Zhang; Fei Fu; Jun-Ping Kou; Bo-Yang Yu; Fang Li
Journal:  Acta Pharmacol Sin       Date:  2021-12-16       Impact factor: 7.169

4.  Puerarin attenuates isoproterenol‑induced myocardial hypertrophy via inhibition of the Wnt/β‑catenin signaling pathway.

Authors:  Xiaoying Wang; Kai He; Linlin Ma; Lan Wu; Yan Yang; Yanfei Li
Journal:  Mol Med Rep       Date:  2022-08-10       Impact factor: 3.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.